Challenger receives $11.80 per share indicative offer from Daiichi Life subsidiary
Challenger Limited (ASX: CGF) has received a non-binding and conditional indicative offer from TAL Daiichi Life Australia Pty Limited (TDA), a subsidiary of Daiichi Life Group, Inc. (Daiichi Life). The takeover offer is proposed at $11.80 per share.
TDA proposes to acquire the remaining 79.5% of ordinary shares in Challenger it does not already own, increasing its ownership to 100%, by way of a scheme of arrangement. The proposal was received after market close on Friday 16 October 2026 and announced on 19 October 2026.
The Board of Challenger is considering the indicative offer. Challenger shareholders do not need to take any action in response to the indicative offer.
When big ASX news breaks, our subscribers know first
Offer sits at a 17.7% premium to Challenger’s one-month VWAP
Challenger noted that the offer represents a 17.7% premium to its one-month volume weighted average price (VWAP) of $10.03. VWAP is the average price of a stock over a period, weighted by the number of shares traded at each price.
The premium gives shareholders a reference point for how the proposed price compares with recent trading. The key terms of the indicative offer are summarised below.
The proposal arrives after Challenger’s FY26 earnings showed normalised NPAT of $468 million, record annuity sales and an upsized buy-back, giving the Board a strong operating backdrop against which to assess the indicative price.
| Metric | Detail |
|---|---|
| Offer price | $11.80 per share |
| One-month VWAP | $10.03 |
| Premium | 17.7% |
| Stake sought | Remaining 79.5% |
| Structure | Scheme of arrangement |
The announcement does not disclose a total transaction value or equity valuation.
What is a scheme of arrangement?
A scheme of arrangement is a court-approved process in which a bidder acquires all of a company’s shares. It requires shareholder approval.
A non-binding indicative offer is an early step rather than a completed deal. Challenger stated the proposal is subject to a number of conditions, including:
- Satisfactory completion of due diligence
- Entry into a scheme implementation agreement on acceptable terms
- Approval from various regulatory bodies
- Board recommendation
The Board has not recommended the offer. It is considering the indicative offer.
What happens next for Challenger shareholders
Challenger stated there is no certainty the proposal will result in a binding offer or that any transaction will eventuate. The announcement does not disclose dates for the Board’s response or the due diligence period.
Challenger said it will continue to keep the market informed in accordance with its continuous disclosure obligations.
Key disclosure
Challenger shareholders do not need to take any action in response to the indicative offer.
Established in 1985, Challenger describes itself as “Australia’s leading retirement income business”. It runs an APRA-regulated life company and is listed on the Australian Securities Exchange (ASX). It also provides income solutions for institutional investors through its credit origination capabilities.
Investors may wish to watch for further ASX announcements as the Board considers the indicative offer.
For readers wanting to understand what a buyer would be acquiring, our full explainer on Challenger’s retirement growth strategy covers its roughly 90% annuities market share, the Calix Re platform and the new earnings reporting framework due from FY27.
Don’t Miss the Next Financials Takeover Move
Get FREE breaking ASX news on financials and other non-resource sectors delivered to your inbox within minutes of release, complete with in-depth analysis. Join 20,000+ investors already receiving alerts from Big News Blast. Click the “Free Alerts” button to see market-moving announcements the moment they break.